Addex Therapeutics grants Nunn 943K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. director Jason Raleigh Nunn received a grant of 942,854 stock options on November 11, 2026, bringing his directly held options after the grant to 992,854. The options have an exercise price of $0.026 per share and vest in equal monthly installments over four years beginning at the exercisable date. Each option gives the right to purchase one ADXN share listed on SIX Swiss Exchange.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 942,854 | $0.00 | $0.00 |
Footnotes (2)
- F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Key Figures
Key Terms
stock-option financial
exercise price financial
exercisable date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did the ADXN director receive?
What is the exercise price of the ADXN stock options?
AI-generated analysis. How Rhea-AI works. Not financial advice.